RESUMO
HLA-DPB1*1618:01 differs from HLA-DPB1*18:01:01:01 by one nucleotide substitution in codon 215 in exon 4.
Assuntos
Alelos , Sequência de Bases , Éxons , Cadeias beta de HLA-DP , Teste de Histocompatibilidade , Análise de Sequência de DNA , Humanos , Cadeias beta de HLA-DP/genética , Teste de Histocompatibilidade/métodos , Análise de Sequência de DNA/métodos , Códon , Alinhamento de Sequência , Doadores de Tecidos , Polimorfismo de Nucleotídeo Único , Substituição de AminoácidosRESUMO
HLA-DPB1*21:01:02 differs from HLA-DPB1*21:01:01 by one single nucleotide substitution at position 435 C>T in exon 3.
Assuntos
Alelos , Éxons , Cadeias beta de HLA-DP , Teste de Histocompatibilidade , Sequenciamento por Nanoporos , Humanos , Cadeias beta de HLA-DP/genética , Teste de Histocompatibilidade/métodos , Sequenciamento por Nanoporos/métodos , Polimorfismo de Nucleotídeo Único , Sequência de Bases , Análise de Sequência de DNA/métodos , Doadores de Tecidos , Alinhamento de SequênciaRESUMO
The novel HLA-DPB1*14:01:15 allele differs from DPB1*14:01:01:01 by change of C > T in exon 3.
Assuntos
Alelos , Sequência de Bases , Éxons , Cadeias beta de HLA-DP , Teste de Histocompatibilidade , Doadores de Tecidos , Humanos , Cadeias beta de HLA-DP/genética , Brasil , Análise de Sequência de DNA/métodos , Medula Óssea , Alinhamento de Sequência , Códon , Transplante de Medula ÓsseaRESUMO
Nucleotide substitution in the intron 2 of HLA-DPB1*04:02:01:01 results in a novel allele, HLA-DPB1*04:02:01:44.
Assuntos
Alelos , Sequência de Bases , Cadeias beta de HLA-DP , Teste de Histocompatibilidade , Íntrons , Análise de Sequência de DNA , Doadores de Tecidos , Humanos , Cadeias beta de HLA-DP/genética , Análise de Sequência de DNA/métodos , Éxons , Alinhamento de Sequência , Medula Óssea , CódonRESUMO
To analyse the effect of HLA-DPA1 and HLA-DPB1 allelic mismatches on the outcomes of unrelated donor haematopoietic stem cell transplantation (URD-HSCT), we collected 258 recipients with haematological disease who underwent HLA-10/10 matched URD-HSCT. HLA-A, -B, -C, -DRB1, -DQB1, -DRB3/4/5, -DQA1, -DPA1 and -DPB1 typing was performed for the donors and recipients using next-generation sequencing (NGS) technology. After excluding 8 cases with DQA1 or DRB3/4/5 mismatches, we included 250 cases with HLA-14/14 matching for further analysis. Our results showed that the proportion of matched DPA1 and DPB1 alleles was only 10.4% (26/250). The remaining 89.6% of donors and recipients demonstrated DPA1 or DPB1 mismatch. In the DPA1 matched and DPB1 mismatched group, accounting for 18.8% (47/250) of the cohort, DPB1*02:01/DPB1*03:01 allelic mismatches were associated with decreased 2-year OS and increased NRM. DPB1*02:02/DPB1*05:01 and DPB1*02:01/DPB1*05:01 mismatches showed no impact on outcomes. Moreover, the specific allelic mismatches observed were consistent with the DPB1 T-cell epitope (TCE) classification as permissive and non-permissive. We innovatively established an analysis method for DPA1 ~ DPB1 linkage mismatch for cases with both DPA1 and DPB1 mismatched, accounting for 70% (175/250) of the total. DPA1*02:02 ~ DPB1*05:01/DPA1*02:01 ~ DPB1*17:01 linkage mismatches were associated with lower 2-year OS, especially among AML/MDS recipients. DPA1*02:02 ~ DPB1*05:01/DPA1*01:03 ~ DPB1*02:01 linkage mismatches showed no impact on outcomes. In conclusion, applying the DPA1 ~ DPB1 linkage mismatch analysis approach can identify different types of mismatches affecting transplant outcomes and provide valuable insight for selecting optimal donors for AML/MDS and ALL recipients.
Assuntos
Alelos , Cadeias alfa de HLA-DP , Cadeias beta de HLA-DP , Transplante de Células-Tronco Hematopoéticas , Teste de Histocompatibilidade , Doadores não Relacionados , Humanos , Cadeias beta de HLA-DP/genética , Transplante de Células-Tronco Hematopoéticas/métodos , Cadeias alfa de HLA-DP/genética , Masculino , Teste de Histocompatibilidade/métodos , Feminino , Adulto , Pessoa de Meia-Idade , Adolescente , Adulto Jovem , Criança , Pré-Escolar , Idoso , Sequenciamento de Nucleotídeos em Larga Escala/métodos , Doença Enxerto-Hospedeiro/genética , Doença Enxerto-Hospedeiro/imunologiaRESUMO
HLA-DPB1*1553:01 differs from HLA-DPB1*09:01:01:01 by one nucleotide in exon 3.
Assuntos
Éxons , Cadeias beta de HLA-DP , Teste de Histocompatibilidade , Humanos , Alelos , Sequência de Bases , Códon , População do Leste Asiático , Cadeias beta de HLA-DP/genética , Alinhamento de Sequência , Análise de Sequência de DNA/métodos , Doadores de TecidosRESUMO
Background: Screening and treating healthcare workers (HCWs) for latent tuberculosis infection (LTBI) are essential for tuberculosis (TB) infection control. Adverse drug reactions (ADRs) to anti-TB drugs present challenges to patient safety and treatment completion. Objective: This study investigated the association between human leukocyte antigen (HLA) alleles and the risk of ADRs, especially drug hypersensitivity (DHS) and hepatotoxicity, in HCWs with LTBI receiving isoniazid (INH) and rifampin (RIF) therapy. Methods: Korean HCWs with LTBI who received a 3 month INH and RIF regimen were included in this study. HLA genotyping was performed on HCWs who experienced ADRs during treatment, as well as the control group consisted of individuals who did not develop ADRs. Results: Of the 67 patients, 29 (43.2%) experienced ADRs during INH and RIF therapy. The HLA-A*11:01 allele was more frequent in patients with DHS without hepatotoxicity (DSH+/H-) compared to the control group (DHS-/H-) (4/9, 44.4% vs. 3/38, 7.9%; odd ratio [OR], 8.554; 95% confidence interval [CI], 1.415-59.869; p = 0.018). Conversely, HLA-DPB1*05:01 was associated with an increased risk of hepatotoxicity regardless of DHS (10/20, 50% vs. 5/38, 13.2%; OR, 5.323; 95% CI, 1.493-21.518; p = 0.011). In the DHS with hepatotoxicity group (DHS+/H+), HLA-DPB1*05:01 was present in a higher proportion (3/5, 60% vs. 5/38, 13.2%; OR, 8.912; 95% CI, 1.110-92.993; p = 0.037), whereas HLA-A*11:01 was not observed in this group. Conclusions: The HLA-A*11:01 allele was associated with an increased risk of DHS without hepatotoxicity, whereas the HLA-DPB1*05:01 allele was associated with an increased risk of hepatotoxicity.
RESUMO
HLA-DPB1*05:01:20 differs from HLA-DPB1*05:01:01:01 by one nucleotide in exon 3.
Assuntos
Alelos , Povo Asiático , Sequência de Bases , Éxons , Cadeias beta de HLA-DP , Teste de Histocompatibilidade , Análise de Sequência de DNA , Humanos , Cadeias beta de HLA-DP/genética , Povo Asiático/genética , Análise de Sequência de DNA/métodos , Doadores de Tecidos , Alinhamento de Sequência , Códon , População do Leste AsiáticoRESUMO
The novel allele HLA-DPB1*1467:01 differs from HLA-DPB1*09:01:01:01 by one non-synonymous nucleotide substitution in exon 2.
Assuntos
Sequência de Bases , Humanos , Alelos , Cadeias beta de HLA-DP/genética , Éxons/genética , Análise de Sequência de DNARESUMO
The novel HLA-DPB1*1437:01 and HLA-DPB1*1438:01 alleles first identified in the Chinese individuals.
Assuntos
Sequenciamento de Nucleotídeos em Larga Escala , Humanos , Alelos , Cadeias beta de HLA-DP/genéticaRESUMO
HLA-DPB1*1500:01N differs from HLA-DPB1*05:01:01:01 by one nucleotide in exon 3.
Assuntos
Cadeias beta de HLA-DP , Nucleotídeos , Humanos , Alelos , Sequência de Bases , China , Análise de Sequência de DNARESUMO
HLA-DPB1*03:01:29 differs from HLA-DPB1*03:01:01:01 by one nucleotide in exon 2.
Assuntos
Cadeias beta de HLA-DP , Nucleotídeos , Humanos , Alelos , Análise de Sequência de DNA , ChinaRESUMO
HLA-DPB1*1584:01 differs from HLA-DPB1*104:01:01:03 by one nucleotide substitution in exon 2.
Assuntos
Sequenciamento de Nucleotídeos em Larga Escala , Humanos , Sequência de Bases , Alelos , Cadeias beta de HLA-DP/genéticaRESUMO
The novel HLA-DPB1*1449:01N allele differs from HLA-DPB1*16:01:01:01 by a nucleotide at codon 92 in exon 2.
Assuntos
Sequenciamento de Nucleotídeos em Larga Escala , Humanos , Alelos , Éxons/genética , Cadeias beta de HLA-DP/genéticaRESUMO
HLA-DPB1*05:01:21 differs from HLA-DPB1*05:01:01:01 by one nucleotide in exon 3.
Assuntos
Cadeias beta de HLA-DP , Nucleotídeos , Humanos , Alelos , Sequência de Bases , ChinaRESUMO
HLA-DPB1*1550:01 differs from HLA-DPB1*02:02:01:01 by one nucleotide in exon 2.
Assuntos
Cadeias beta de HLA-DP , Nucleotídeos , Humanos , Alelos , Sequência de Bases , ChinaRESUMO
HLA-C*12:02:52 differs from HLA-C*12:02:02:01 by one nucleotide in exon 1.
Assuntos
Genes MHC Classe I , Antígenos HLA-C , Humanos , Antígenos HLA-C/genética , Alelos , Nucleotídeos , China , Análise de Sequência de DNARESUMO
Two novel alleles, HLA-G*01:04:09 and HLA-DPB1*04:01:01:136, were identified in a single healthy individual.
Assuntos
Genes MHC Classe I , Antígenos HLA-G , Humanos , Alelos , Cadeias beta de HLA-DP/genéticaRESUMO
HLA-DPB1*1516:01 differs from HLA-DPB1*1229:01 by seven nucleotide substitutions in exon 3.
Assuntos
Sequência de Bases , Humanos , Alelos , Cadeias beta de HLA-DP/genética , Éxons/genéticaRESUMO
Characterization of two novel HLA-DPB1 alleles: HLA-DPB1*1069:01, and DPB1*1072:01 containing non-synonymous nucleotide substitutions.